首页 | 本学科首页   官方微博 | 高级检索  
检索        

肝细胞癌四种临床分期系统预后判断和治疗指导价值的比较
引用本文:朱燕娟,陈晓泓,张博恒,邱双健,樊嘉,任正刚,夏景林,王艳红,干育红,叶胜龙.肝细胞癌四种临床分期系统预后判断和治疗指导价值的比较[J].中华消化杂志,2010,30(6).
作者姓名:朱燕娟  陈晓泓  张博恒  邱双健  樊嘉  任正刚  夏景林  王艳红  干育红  叶胜龙
作者单位:1. 复旦大学附属中山医院肝癌研究所肝肿瘤内科,上海,200032
2. 复旦大学附属中山医院肝癌研究所肝肿瘤外科,上海,200032
摘    要:目的 比较4个分期系统巴塞罗那临床肝癌分期标准(BCLC)、日本综合分期积分(JIS)、意大利肝癌评分(CLIP)和国内分期]对中国肝癌患者预后判断和对治疗方案选择的指导意义.方法 回顾性分析2001年至2002年复旦大学附属中山医院收治的861例初发肝细胞癌患者的临床资料,分别按4个分期系统分期或评分,比较各期患者的生存情况以及不同治疗方案对其生存的影响.结果 在判断预后方面,BCLC、JIS和国内分期系统的各分期间生存率差异均有统计学意义;而在CLIP分期的一些评分间的生存率差异无统计学意义.在指导治疗方面,BCLC C期,CLIP 3、4分以及国内分期ⅢA期的患者接受手术治疗与接受肝动脉化学治疗栓塞(TACE)和(或)肝动脉栓塞(TAE)治疗的生存率差异无统计学意义;而比这些更早期的患者接受手术治疗的生存率优于接受TACE和(或)TAE治疗的生存率.结论 BCLC、JIS和国内分期系统在判断预后方面适用于中国患者;但仅国内分期和BCLC分期同时兼备了判断预后和指导治疗两方面的作用.

关 键 词:肝细胞癌  分期系统  判断预后  指导治疗

Comparison of four staging systems in predicting outcomes and guiding option of treatment for patients with hepatocellular carcinoma
ZHU Yan-juan,CHEN Xiao-hong,ZHANG Bo-heng,QIU Shuang-jian,FAN Jia,REN Zheng-gang,XIA Jin-lin,WANG Yan-hong,GAN Yu-hong,YE Sheng-long.Comparison of four staging systems in predicting outcomes and guiding option of treatment for patients with hepatocellular carcinoma[J].Chinese Journal of Digestion,2010,30(6).
Authors:ZHU Yan-juan  CHEN Xiao-hong  ZHANG Bo-heng  QIU Shuang-jian  FAN Jia  REN Zheng-gang  XIA Jin-lin  WANG Yan-hong  GAN Yu-hong  YE Sheng-long
Abstract:Objective To compare the Barcelona clinic liver cancer staging classification (BCLC), the Japan integrated staging score (JIS), the cancer of the liver Italian program score (CLIP) and Chinese staging system in terms of their ability to predict outcomes and to guide option of therapy in patients with hepatocellular carcinoma (HCC) in China.Methods Clinical data of 861 HCC patients from Zhongshan Hospital between 2001 and 2002 were retrospectively analyzed. Patients were classified acccording to different staging systems. Survival for patients in different stages and the effects of therapeutic methods on survival time were compared. Results BCLC, JIS and Chinese staging system showed the ability in predicting survival for patients in different staging. CLIP failed to show significant difference in survival rates for each subgroup. There was no significant difference in survival rate between surgery and transarterial chemoembolization (TACE)/transarterial embolization (TAE) for patients classified as BCLC stage C, CLIP scores more than 3 or Chinese stage Ⅲ a.The survival rate, however, was higher in patients received operation than those received TACE/TAE if they were classified as earlier stages. Conclusions The BCLC, JIS and Chinese staging systems show prospective ability for Chinese HCC patients in prediction outcomes, whereas the BCLC and the Chinese staging systems are better at both predicting outcomes and guiding the option of treatment.
Keywords:Hepatocellular carcinoma  Staging systems  Prognostic ability  Therapeutic guiding ability
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号